BLADMIR 25 10S

About

Bladmir, containing Mirabegron, is a novel medication classified as a beta-3 adrenergic agonist, specifically designed for the treatment of overactive bladder (OAB) syndrome. OAB is characterized by symptoms such as urinary urgency, increased urinary frequency, and urge incontinence. Mirabegron works by selectively activating beta-3 adrenergic receptors located on the detrusor muscle of the bladder. This activation leads to the relaxation of the detrusor muscle during the urine storage phase of the bladder fill-void cycle, which in turn increases the bladder's capacity to hold urine without causing involuntary contractions. This mechanism of action is distinct from anticholinergic medications, offering an important alternative for patients who may not tolerate the common side effects of anticholinergics, such as dry mouth and constipation, or for whom anticholinergics are contraindicated. By improving bladder storage function, Mirabegron effectively reduces OAB symptoms, thereby significantly enhancing the patient's quality of life and bladder control.

Uses

• Treatment of overactive bladder (OAB) symptoms.
• Reduction of urinary urgency.
• Decrease in urinary frequency.
• Management of urge incontinence.

Directions For Use

Take one 25mg tablet once daily with water, with or without food, as directed by your physician. Swallow the tablet whole; do not chew, crush, or divide.

Benefits

• Reduces urinary urgency and frequency.
• Decreases episodes of urge incontinence.
• Increases bladder capacity.
• Offers an alternative to anticholinergic OAB treatments.
• Improves quality of life for OAB patients.
• Generally well-tolerated.

Side Effects

• Hypertension (increased blood pressure)
• Nasopharyngitis (common cold)
• Urinary tract infection (UTI)
• Headache
• Tachycardia (increased heart rate)
• Dizziness
• Constipation
• Dry mouth
• Nausea
• Abdominal pain
• Diarrhea
• Arthralgia (joint pain)

Safety Measures

• Alcohol - No specific interaction with alcohol is generally noted for Mirabegron.
• Pregnancy - Not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. Consult a doctor.
• Breastfeeding - Not recommended during breastfeeding as Mirabegron is excreted in milk in animals, and human data is lacking.
• Liver - Use with caution in patients with moderate liver impairment; contraindicated in severe liver impairment.
• Kidney - Use with caution in patients with moderate to severe kidney impairment; contraindicated in end-stage renal disease requiring hemodialysis.
• Lung - No specific contraindications or precautions related to lung conditions are generally noted for Mirabegron.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.